Topic: Sickle Cell Disease

Interventions of Interest: Despite uncertainty regarding longer-term outcomes, lovo-cel and exa-cel both estimated to produce substantial gains in length and quality of life; independent appraisal committee voted that currently available evidence is adequate to demonstrate a net health benefit over standard of care. Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for […]

Interventions of Interest: Crizanlizumab (Adakveo®, Novartis) Voxelotor (Oxbryta®, Global Blood Therapeutics) L-gluatmine (Endari, Emmaus Medical) Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings. […]